After decades of decline that once had public health officials discussing syphilis elimination as a realistic near-term goal, rates have risen substantially in recent years, including a particularly troubling increase in congenital syphilis — infection passed from mother to infant during pregnancy — a case category with severe, entirely preventable consequences when maternal screening and treatment occur appropriately.
Congenital Syphilis Is the Starkest Marker of the Overall Trend
Congenital syphilis cases have risen sharply, and because this outcome is directly preventable through maternal screening and treatment during pregnancy, its rise serves as a particularly visible marker of gaps in prenatal care access and screening consistency — every congenital syphilis case represents, by definition, a missed or delayed opportunity for prevention at some point in the maternal care pathway, making this outcome category a focus of targeted public health response distinct from adult syphilis trends generally.
Reduced Public Health Infrastructure Investment Contributed to the Trend
Public health researchers examining the resurgence have pointed to reduced funding and staffing for sexually transmitted infection prevention programs, including disease intervention specialists who traditionally conducted partner notification and contact tracing, as a contributing structural factor — this decades-long infrastructure erosion left the public health system less equipped to respond quickly once case rates began climbing, a lag effect that compounded the resurgence once it began.
Screening Guideline Expansion Reflects the Changed Risk Landscape
In response to rising rates, screening guidelines have expanded recommended syphilis testing frequency and populations, including more frequent screening during pregnancy given the congenital syphilis stakes specifically, and broader risk-based screening recommendations for sexually active adults generally. Guideline expansion alone does not guarantee implementation, however, and actual screening rates in routine practice have lagged the updated recommendations in various care settings.
Penicillin Remains the Standard Treatment, With a Documented Supply Vulnerability
Benzathine penicillin G remains the standard, highly effective treatment for syphilis, including during pregnancy where it is the only treatment considered adequate to prevent congenital transmission — this reliance on a single formulation has created real vulnerability during periods of manufacturer supply shortage, situations that have prompted emergency prioritization protocols to ensure pregnant patients specifically receive available supply given the stakes of untreated maternal infection.
Rapid Point-of-Care Testing Has Expanded Access in Some Settings
Rapid point-of-care syphilis testing, providing results within minutes rather than requiring laboratory processing and a follow-up visit, has expanded testing access in emergency departments, prenatal care settings, and community health settings where patients may not reliably return for a second visit to receive standard laboratory test results — this technology addresses a specific care-cascade drop-off point similar to the pattern seen in other infectious disease screening programs.
Conclusion
The syphilis resurgence, and particularly the rise in preventable congenital cases, reflects a combination of eroded public health infrastructure, screening implementation gaps, and, at times, treatment supply vulnerability — a response requiring coordinated screening expansion and reliable treatment access rather than any single fix. Facilities expanding syphilis screening and treatment capacity depend on reliable lab supplies and pharmacy access to support this response.
